Format

Send to

Choose Destination
Int J Infect Dis. 2013 Oct;17(10):e792-8. doi: 10.1016/j.ijid.2013.07.002. Epub 2013 Aug 29.

Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.

Author information

1
Pharmacy Services Division, Saudi Aramco Medical Services Organization, Dhahran, Saudi Arabia.

Abstract

The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically related to the SARS coronavirus and has also been associated with severe respiratory illness as well as nosocomial transmission in healthcare settings. Current international recommendations do not support any specific therapies; however, there are a number of agents, which were used during the SARS epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to their potential use in patients with MERS-CoV infections.

KEYWORDS:

Interferon; MERS-CoV; Ribavarin; SARS

PMID:
23993766
DOI:
10.1016/j.ijid.2013.07.002
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center